21.01.2025 16:15:00

Where Will Moderna Be in 3 Years?

As Moderna (NASDAQ: MRNA) looks to shore up its business in the wake of its declining coronavirus vaccine sales, it's natural for investors to wonder about where the biotech will go in the near future.By early 2028, Moderna will be firmly within its next phase of life, potentially operating more like a traditional pharmaceutical business than like an up-and-coming biotech with a lot to prove about the value of its platform and its general competency in drug development.The question is, will that phase be better than the one it just exited? Let's investigate what it's working on and the financial impacts that work could have for investors.Continue readingWeiter zum vollständigen Artikel bei MotleyFool

Analysen zu Moderna Incmehr Analysen

19.11.24 Moderna Hold Joh. Berenberg, Gossler & Co. KG (Berenberg Bank)
13.09.24 Moderna Underweight JP Morgan Chase & Co.
05.08.24 Moderna Sector Perform RBC Capital Markets
12.01.24 Moderna Outperform RBC Capital Markets
03.11.23 Moderna Buy Goldman Sachs Group Inc.
Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

:be AG Inhaber-Akt 1,39 0,00% :be AG Inhaber-Akt
Moderna Inc 34,35 -2,15% Moderna Inc